RWA Wealth Partners LLC Sells 142 Shares of Vertex Pharmaceuticals Incorporated $VRTX

RWA Wealth Partners LLC lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,343 shares of the pharmaceutical company’s stock after selling 142 shares during the quarter. RWA Wealth Partners LLC’s holdings in Vertex Pharmaceuticals were worth $1,043,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of VRTX. Price T Rowe Associates Inc. MD lifted its stake in shares of Vertex Pharmaceuticals by 72.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company’s stock valued at $1,414,331,000 after buying an additional 1,226,527 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Vertex Pharmaceuticals by 21.5% in the 2nd quarter. Jennison Associates LLC now owns 6,151,505 shares of the pharmaceutical company’s stock worth $2,738,650,000 after acquiring an additional 1,089,063 shares during the last quarter. Nuveen LLC bought a new position in Vertex Pharmaceuticals in the 1st quarter valued at about $484,053,000. Goldman Sachs Group Inc. boosted its stake in Vertex Pharmaceuticals by 28.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,775,194 shares of the pharmaceutical company’s stock valued at $860,650,000 after purchasing an additional 398,460 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its stake in Vertex Pharmaceuticals by 456.9% during the 1st quarter. Alyeska Investment Group L.P. now owns 431,804 shares of the pharmaceutical company’s stock valued at $209,347,000 after purchasing an additional 354,269 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $409.47 on Monday. The firm has a market cap of $103.89 billion, a price-to-earnings ratio of 29.27 and a beta of 0.36. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.88. The firm’s 50-day simple moving average is $404.55 and its two-hundred day simple moving average is $429.12.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the prior year, the firm earned $4.38 EPS. The company’s revenue was up 11.0% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on VRTX. UBS Group lowered their price objective on Vertex Pharmaceuticals from $553.00 to $546.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings reissued a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 8th. Morgan Stanley dropped their price objective on Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Citigroup lifted their price objective on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a report on Thursday, October 2nd. Finally, BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $489.10.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.